Listed: 2023/02/14
Transfer of a university-spawned biotech business based on microalgae technology (patents, know-how) (Ibaraki, share transfer)
KantoMedical
Business description
■Business Model
・Business overview
Guided by the vision of "contributing to global healthcare through microalgae technology," the company extracts DHA and other compounds from microalgae and develops them into health foods, supplements, pharmaceuticals, and more.
・Product and service features
Products for the general food market have already been launched, and the company plans to accelerate its product rollout going forward.
・Customer and client features
DHA and other compounds are extracted from microalgae and sold as algal biomass or extracted oil to food and supplement manufacturers, among others.
・Staff and organizational features
Led by the CEO, the team is rich in personnel with backgrounds in the biotech field (4 PhD holders).
・Strengths and selling points
Key strengths related to the microalgae business include the following:
(1) Proprietary strain-improvement technology
(2) Proprietary cultivation-optimization technology
(3) An extensive strain library
(4) Relevant intellectual property already secured
Machine translated from the original Japanese listing. View original (Japanese)
Annual operating profit
--〜--
Assets
--〜--
Liabilities
--〜--
Net assets
--〜--
Assets to be transferred
会社譲渡
Reason for sale
その他
Reason for sale (details)
資本獲得による事業拡大、ファンド運用期間終了のため、取引条件については柔軟な対応が可能です。
Products and services
■希望売却価格
5億円
※取引条件については柔軟な対応が可能です。
■売却形式
株式譲渡
■売却理由
資本獲得による事業拡大
■財務情報
・売上高：0円〜1,000万円
・営業利益：▲1,000万円未満
※役員報酬1,000万円〜2,000万円、金融借入金なし
Asking price¥500M–¥500M